Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative)

v3.19.2
Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 12, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Common stock, shares authorized   100,000,000   100,000,000   100,000,000
Common stock, par value per share   $ 0.001   $ 0.001   $ 0.001
Common stock, shares issued   34,139,220   34,139,220   27,142,979
Common stock, shares outstanding   34,139,220   34,139,220   27,142,979
Number of shares issued       5,480,000    
Gross proceeds from issuance of common stock       $ 5,480,000  
Placement agent fees and legal fees       $ 101,098    
Senior Secured Convertible Note conversion, shares issued       1,516,241    
Stock-based compensation expense   $ 388,363 $ 303,890 $ 847,049 $ 575,176  
Lucid Diagnostics Inc [Member]            
Common stock, shares issued   10,000,000   10,000,000   10,000,000
Common stock, shares outstanding   10,000,000   10,000,000   10,000,000
Majority ownership interest percentage   81.875%   81.875%   81.875%
Lucid Diagnostics Inc [Member] | Noncontrolling Interest [Member]            
Majority ownership interest percentage   18.125%   18.125%   18.125%
Subsequent Event [Member]            
Senior Secured Convertible Note conversion, shares issued 921,929          
Placement Agency Agreement [Member]            
Number of shares issued       530,000    
Individual Investors [Member]            
Number of shares issued       4,950,000